Radiation
Stereotactic Ablative Body Radiotherapy (SABR)
Stereotactic Ablative Body Radiotherapy (SABR) is a radiation therapy with 4 clinical trials. Currently 3 active trials ongoing.
Total Trials
4
Max Phase
—
Type
RADIATION
Molecule
—
Success Metrics
Active Trials
3(75%)
Phase Distribution
Ph phase_3
1
25%
Ph phase_2
1
25%
Ph not_applicable
1
25%
Ph phase_1
1
25%
Phase Distribution
1
Early Stage
1
Mid Stage
1
Late Stage
Phase Distribution4 total trials
Phase 1Safety & dosage
1(25.0%)
Phase 2Efficacy & side effects
1(25.0%)
Phase 3Large-scale testing
1(25.0%)
N/ANon-phased studies
1(25.0%)
Highest Phase Reached
Phase 3Trial Status & Enrollment
Completion Rate
0.0%
0 of 0 finished
Non-Completion Rate
0.0%
0 ended early
Currently Active
3
trials recruiting
Total Trials
4
all time
Status Distribution
Active(3)
Other(1)
Detailed Status
Recruiting2
Active, not recruiting1
unknown1
Development Timeline
Analytics
Development Status
Total Trials
4
Active
3
Success Rate
N/A
Most Advanced
Phase 3
Trials by Phase
Phase 11 (25.0%)
Phase 21 (25.0%)
Phase 31 (25.0%)
N/A1 (25.0%)
Trials by Status
recruiting250%
active_not_recruiting125%
unknown125%
Recent Activity
3 active trials
Showing 4 of 4
active_not_recruitingphase_1
Radiation Therapy in Combination With Durvalumab for People With Pancreatic Cancer
NCT03245541
recruitingphase_3
A Randomised Controlled Platform Trial Testing Treatments in Metastatic Hormone Sensitive Prostate Cancer
NCT06320067
recruitingphase_2
SABR Combined with Axitinib and Toripalimab in Recurrent or Metastatic RCC
NCT06889649
unknownnot_applicable
Neoadjuvant Stereotactic Ablative Radiotherapy for Pancreatic Ductal Adenocarcinoma
NCT04915417
Clinical Trials (4)
Showing 4 of 4 trials
NCT03245541Phase 1
Radiation Therapy in Combination With Durvalumab for People With Pancreatic Cancer
NCT06320067Phase 3
A Randomised Controlled Platform Trial Testing Treatments in Metastatic Hormone Sensitive Prostate Cancer
NCT06889649Phase 2
SABR Combined with Axitinib and Toripalimab in Recurrent or Metastatic RCC
NCT04915417Not Applicable
Neoadjuvant Stereotactic Ablative Radiotherapy for Pancreatic Ductal Adenocarcinoma
All 4 trials loaded
Drug Details
- Intervention Type
- RADIATION
- Total Trials
- 4